ID   MP2K2_HUMAN             Reviewed;         400 AA.
AC   P36507;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-1994, sequence version 1.
DT   05-OCT-2010, entry version 127.
DE   RecName: Full=Dual specificity mitogen-activated protein kinase kinase 2;
DE            Short=MAP kinase kinase 2;
DE            Short=MAPKK 2;
DE            EC=2.7.12.2;
DE   AltName: Full=ERK activator kinase 2;
DE   AltName: Full=MAPK/ERK kinase 2;
DE            Short=MEK 2;
GN   Name=MAP2K2; Synonyms=MEK2, MKK2, PRKMK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=93266604; PubMed=8388392;
RA   Zheng C.-F., Guan K.-L.;
RT   "Cloning and characterization of two distinct human extracellular
RT   signal-regulated kinase activator kinases, MEK1 and MEK2.";
RL   J. Biol. Chem. 268:11435-11439(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Muscle, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   PROTEIN SEQUENCE OF 40-51; 53-61; 64-100; 102-112; 164-172; 194-205;
RP   265-297; 362-371 AND 389-397, PHOSPHORYLATION AT THR-394, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Colon carcinoma;
RA   Bienvenut W.V., Zebisch A., Kolch W.;
RL   Submitted (DEC-2008) to UniProtKB.
RN   [4]
RP   PROTEIN SEQUENCE OF 210-231, INACTIVATION BY YERSINIA YOPJ,
RP   PHOSPHORYLATION AT SER-222 AND SER-226, ACETYLATION AT SER-222 AND
RP   SER-226, AND MASS SPECTROMETRY.
RX   PubMed=17116858; DOI=10.1073/pnas.0608995103;
RA   Mittal R., Peak-Chew S.Y., McMahon H.T.;
RT   "Acetylation of MEK2 and I kappa B kinase (IKK) activation loop
RT   residues by YopJ inhibits signaling.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:18574-18579(2006).
RN   [5]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   MEDLINE=98230732; PubMed=9563949; DOI=10.1126/science.280.5364.734;
RA   Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R.,
RA   Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D.,
RA   Vande Woude G.F.;
RT   "Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal
RT   factor.";
RL   Science 280:734-737(1998).
RN   [6]
RP   CLEAVAGE BY ANTHRAX LETHAL FACTOR.
RX   MEDLINE=20558083; PubMed=11104681; DOI=10.1042/0264-6021:3520739;
RA   Vitale G., Bernardi L., Napolitani G., Mock M., Montecucco C.;
RT   "Susceptibility of mitogen-activated protein kinase kinase family
RT   members to proteolysis by anthrax lethal factor.";
RL   Biochem. J. 352:739-745(2000).
RN   [7]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23 AND THR-394, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-396, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND THR-394, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=17192257; DOI=10.1074/mcp.T600062-MCP200;
RA   Wissing J., Jaensch L., Nimtz M., Dieterich G., Hornberger R.,
RA   Keri G., Wehland J., Daub H.;
RT   "Proteomics analysis of protein kinases by target class-selective
RT   prefractionation and tandem mass spectrometry.";
RL   Mol. Cell. Proteomics 6:537-547(2007).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-396, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18187866; DOI=10.2116/analsci.24.161;
RA   Imami K., Sugiyama N., Kyono Y., Tomita M., Ishihama Y.;
RT   "Automated phosphoproteome analysis for cultured cancer cells by two-
RT   dimensional nanoLC-MS using a calcined titania/C18 biphasic column.";
RL   Anal. Sci. 24:161-166(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394 AND THR-396, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-293; SER-295 AND
RP   THR-396, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-222; SER-226; THR-394
RP   AND THR-396, AND MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, PHOSPHORYLATION [LARGE
RP   SCALE ANALYSIS] AT THR-394, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-23; SER-222; SER-226;
RP   SER-293; SER-295 AND THR-396, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-394, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   VARIANT CFC SYNDROME CYS-57.
RX   PubMed=16439621; DOI=10.1126/science.1124642;
RA   Rodriguez-Viciana P., Tetsu O., Tidyman W.E., Estep A.L., Conger B.A.,
RA   Cruz M.S., McCormick F., Rauen K.A.;
RT   "Germline mutations in genes within the MAPK pathway cause cardio-
RT   facio-cutaneous syndrome.";
RL   Science 311:1287-1290(2006).
CC   -!- FUNCTION: Catalyzes the concomitant phosphorylation of a threonine
CC       and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP
CC       kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity).
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with MORG1 (By similarity).
CC   -!- INTERACTION:
CC       P10398:ARAF; NbExp=3; IntAct=EBI-1056930, EBI-365961;
CC   -!- PTM: MAPKK is itself dependent on Ser/Thr phosphorylation for
CC       activity catalyzed by MAP kinase kinase kinases (RAF or MEKK1).
CC   -!- PTM: Acetylation of Ser-222 and Ser-226 by Yersinia yopJ prevents
CC       phosphorylation and activation, thus blocking the MAPK signaling
CC       pathway.
CC   -!- DISEASE: Defects in MAP2K2 are a cause of cardiofaciocutaneous
CC       syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-
CC       cutaneous syndrome. CFC syndrome is characterized by a distinctive
CC       facial appearance, heart defects and mental retardation. Heart
CC       defects include pulmonic stenosis, atrial septal defects and
CC       hypertrophic cardiomyopathy. Some affected individuals present
CC       with ectodermal abnormalities such as sparse, friable hair,
CC       hyperkeratotic skin lesions and a generalized ichthyosis-like
CC       condition. Typical facial features are similar to Noonan syndrome.
CC       They include high forehead with bitemporal constriction,
CC       hypoplastic supraorbital ridges, downslanting palpebral fissures,
CC       a depressed nasal bridge, and posteriorly angulated ears with
CC       prominent helices. The inheritance of CFC syndrome is autosomal
CC       dominant.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. MAP kinase kinase subfamily.
CC   -!- SIMILARITY: Contains 1 protein kinase domain.
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/MAP2K2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L11285; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; BC000471; AAH00471.1; -; mRNA.
DR   EMBL; BC018645; AAH18645.1; -; mRNA.
DR   IPI; IPI00003783; -.
DR   PIR; A46723; A46723.
DR   RefSeq; NP_109587.1; -.
DR   UniGene; Hs.465627; -.
DR   PDB; 1S9I; X-ray; 3.20 A; A/B=55-400.
DR   PDBsum; 1S9I; -.
DR   ProteinModelPortal; P36507; -.
DR   DIP; DIP-29119N; -.
DR   IntAct; P36507; 16.
DR   MINT; MINT-99667; -.
DR   STRING; P36507; -.
DR   PhosphoSite; P36507; -.
DR   REPRODUCTION-2DPAGE; IPI00003783; -.
DR   PeptideAtlas; P36507; -.
DR   PRIDE; P36507; -.
DR   Ensembl; ENST00000262948; ENSP00000262948; ENSG00000126934.
DR   GeneID; 5605; -.
DR   KEGG; hsa:5605; -.
DR   UCSC; uc002lzk.1; human.
DR   CTD; 5605; -.
DR   GeneCards; GC19M004041; -.
DR   H-InvDB; HIX0014653; -.
DR   H-InvDB; HIX0033655; -.
DR   HGNC; HGNC:6842; MAP2K2.
DR   HPA; CAB003835; -.
DR   MIM; 115150; phenotype.
DR   MIM; 601263; gene.
DR   Orphanet; 1340; Cardiofaciocutaneous syndrome.
DR   PharmGKB; PA30587; -.
DR   eggNOG; prNOG06383; -.
DR   HOGENOM; HBG755340; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; P36507; -.
DR   OMA; FEPICEL; -.
DR   PhylomeDB; P36507; -.
DR   BRENDA; 2.7.12.2; 247.
DR   Pathway_Interaction_DB; anthraxpathway; Cellular roles of Anthrax toxin.
DR   Pathway_Interaction_DB; ceramidepathway; Ceramide signaling pathway.
DR   Pathway_Interaction_DB; cd8tcrdownstreampathway; Downstream signaling in naive CD8+ T cells.
DR   Pathway_Interaction_DB; endothelinpathway; Endothelins.
DR   Pathway_Interaction_DB; fcer1pathway; Fc-epsilon receptor I signaling in mast cells.
DR   Pathway_Interaction_DB; il2_1pathway; IL2-mediated signaling events.
DR   Pathway_Interaction_DB; met_pathway; Signaling events activated by Hepatocyte Growth Factor Receptor (c-Met).
DR   Pathway_Interaction_DB; kitpathway; Signaling events mediated by Stem cell factor receptor (c-Kit).
DR   Reactome; REACT_11061; Signalling by NGF.
DR   Reactome; REACT_16888; Signaling by PDGF.
DR   Reactome; REACT_18266; Axon guidance.
DR   Reactome; REACT_498; Signaling by Insulin receptor.
DR   Reactome; REACT_6900; Signaling in Immune system.
DR   Reactome; REACT_9417; Signaling by EGFR.
DR   NextBio; 21780; -.
DR   PMAP-CutDB; P36507; -.
DR   ArrayExpress; P36507; -.
DR   Bgee; P36507; -.
DR   CleanEx; HS_MAP2K2; -.
DR   Genevestigator; P36507; -.
DR   GermOnline; ENSG00000126934; Homo sapiens.
DR   GO; GO:0005829; C:cytosol; EXP:Reactome.
DR   GO; GO:0005576; C:extracellular region; NAS:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; NAS:UniProtKB.
DR   GO; GO:0005515; F:protein binding; IPI:IntAct.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; NAS:UniProtKB.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0006468; P:protein amino acid phosphorylation; NAS:UniProtKB.
DR   GO; GO:0007265; P:Ras protein signal transduction; EXP:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_cat_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR017442; Se/Thr_prot_kinase-like_dom.
DR   InterPro; IPR008271; Ser/Thr_prot_kinase_AS.
DR   InterPro; IPR002290; Ser/Thr_prot_kinase_dom.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; ATP-binding; Complete proteome;
KW   Direct protein sequencing; Disease mutation; Kinase;
KW   Nucleotide-binding; Phosphoprotein; Serine/threonine-protein kinase;
KW   Transferase; Tyrosine-protein kinase.
FT   CHAIN         1    400       Dual specificity mitogen-activated
FT                                protein kinase kinase 2.
FT                                /FTId=PRO_0000086372.
FT   DOMAIN       72    369       Protein kinase.
FT   NP_BIND      78     86       ATP (By similarity).
FT   COMPBIAS    266    315       Pro-rich.
FT   ACT_SITE    194    194       Proton acceptor (By similarity).
FT   BINDING     101    101       ATP (By similarity).
FT   SITE         10     11       Cleavage; by anthrax lethal factor.
FT   MOD_RES       1      1       N-acetylmethionine.
FT   MOD_RES      23     23       Phosphoserine.
FT   MOD_RES     222    222       O-acetylserine; by Yersinia yopJ;
FT                                alternate.
FT   MOD_RES     222    222       Phosphoserine; by RAF; alternate.
FT   MOD_RES     226    226       O-acetylserine; by Yersinia yopJ;
FT                                alternate.
FT   MOD_RES     226    226       Phosphoserine; alternate.
FT   MOD_RES     293    293       Phosphoserine.
FT   MOD_RES     295    295       Phosphoserine.
FT   MOD_RES     394    394       Phosphothreonine.
FT   MOD_RES     396    396       Phosphothreonine.
FT   VARIANT      57     57       F -> C (in CFC syndrome).
FT                                /FTId=VAR_035095.
FT   HELIX        69     71
FT   STRAND       72     80
FT   STRAND       85     91
FT   TURN         92     94
FT   STRAND       97    103
FT   HELIX       110    119
FT   HELIX       120    122
FT   STRAND      133    148
FT   HELIX       155    161
FT   STRAND      162    164
FT   HELIX       167    186
FT   HELIX       197    199
FT   STRAND      200    202
FT   STRAND      208    210
FT   HELIX       217    222
FT   HELIX       236    239
FT   HELIX       246    262
FT   HELIX       272    279
FT   HELIX       318    327
FT   TURN        335    337
FT   HELIX       340    349
FT   TURN        354    356
FT   HELIX       360    364
FT   HELIX       367    374
FT   HELIX       379    386
SQ   SEQUENCE   400 AA;  44424 MW;  3401D522515C30A5 CRC64;
     MLARRKPVLP ALTINPTIAE GPSPTSEGAS EANLVDLQKK LEELELDEQQ KKRLEAFLTQ
     KAKVGELKDD DFERISELGA GNGGVVTKVQ HRPSGLIMAR KLIHLEIKPA IRNQIIRELQ
     VLHECNSPYI VGFYGAFYSD GEISICMEHM DGGSLDQVLK EAKRIPEEIL GKVSIAVLRG
     LAYLREKHQI MHRDVKPSNI LVNSRGEIKL CDFGVSGQLI DSMANSFVGT RSYMAPERLQ
     GTHYSVQSDI WSMGLSLVEL AVGRYPIPPP DAKELEAIFG RPVVDGEEGE PHSISPRPRP
     PGRPVSGHGM DSRPAMAIFE LLDYIVNEPP PKLPNGVFTP DFQEFVNKCL IKNPAERADL
     KMLTNHTFIK RSEVEEVDFA GWLCKTLRLN QPGTPTRTAV
//
